Paklitaksela toksicitātes novērtēšana krūts un olnīcu vēža pacientēm
Loading...
Date
Authors
Advisor
Journal Title
Journal ISSN
Volume Title
Publisher
Latvijas Universitāte
Language
N/A
Abstract
Paklitaksels ir citostatisks preparāts, kurš pieder pie taksānu grupas. To iegūst pus sintētiskā ceļā no klusā okeāna Tisas mizas (Taxus Baccata). To lieto lielākoties olnīcu vai krūts vēža ārstēšanai, tas var būt progresējošs vai izplatīts vēzis. Zāles lieto arī atsevišķā plaušu vēža (progresējošs ne-sīkšūnu plaušu vēzis NSPV) un citu lokalizāciju audzēju terapijā. Paklitakselu lieto arī īpašā vēža gadījumā, ko sauc par Kapošī sarkomu, kas var būt saistīta ar AIDS, ko izraisa HIV saslimšana, ja cita terapija, piemērām, liposomāla antraciklīnu terapija bijusi nesekmīga. Paklitaksel Actavis darbojas pārtraucot šūnu dalīšanos un tiek lietots, lai novērstu vēža šūnu augšanu. Tas iedarbojas ne tikai uz audzēja, bet arī normālām šūnām, kas ir par iemeslu terapijas toksicitātei un blakusparādībām.
Pētījuma mērķis bija apkopot un analizēt datus par paklitaksela terapijas toksicitāti, lielākoties, asins izmaiņās pirms un pēc paklitaksela terapijas.
Bakalaura darbs izstrādāts LU Medicīnas fakultātes farmācijas programmā., Paula Stradiņa klīniskās universitātes slimnīcas Onkoloģijas nodaļā.
Bakalaura darba vadītāja ir onkoloģe –ķīmijterapeite dr. A. Geriņa – Bērziņa.
Atslēgas vārdi: paklitaksels, krūts vēzis, olnīcu vēzis toksicitātes noteikšana, farmakoloģija.
Paclitaxel is ctostatic drug which belongs to the Taxane group. It is produced in semi-syntetic way from the Taxus baccata bark. It is udes mostly defeating breast and ovarian cancer. Medicine use this drug also to lung cancer and tumor localization of other therapy. Paclitaxel is also used for a specificē cancer alled Kaposhiš sarcoma (KS), which may be asociated with AIDS caused by HIV disease when other treatment, such as liposomal anthacycline therapy has failed. Paclitaxel Actavis works to stop cell division and is used to prevent the growth of cancer cells. It works also on normal cells, which have led to treatment toxicity and side effects. The aim was to collect and analyze data on the toxicity of paclitaxel therapy, mostly in blood changes before and after Paclitaxel therapy. Bachelor’s degree was developed in Faculty of Medicine by Pharmacy programme in Paul Stradins Clinical Hospital. Bachelor’s supervisor is Dr. of chemotherapy – oncologist A. Gerina-Berzina. Key words: paclitaxel, breast cancer, ovarian cancer, toxicity, pharmocology.
Paclitaxel is ctostatic drug which belongs to the Taxane group. It is produced in semi-syntetic way from the Taxus baccata bark. It is udes mostly defeating breast and ovarian cancer. Medicine use this drug also to lung cancer and tumor localization of other therapy. Paclitaxel is also used for a specificē cancer alled Kaposhiš sarcoma (KS), which may be asociated with AIDS caused by HIV disease when other treatment, such as liposomal anthacycline therapy has failed. Paclitaxel Actavis works to stop cell division and is used to prevent the growth of cancer cells. It works also on normal cells, which have led to treatment toxicity and side effects. The aim was to collect and analyze data on the toxicity of paclitaxel therapy, mostly in blood changes before and after Paclitaxel therapy. Bachelor’s degree was developed in Faculty of Medicine by Pharmacy programme in Paul Stradins Clinical Hospital. Bachelor’s supervisor is Dr. of chemotherapy – oncologist A. Gerina-Berzina. Key words: paclitaxel, breast cancer, ovarian cancer, toxicity, pharmocology.